Tumor-infiltrating lymphocytes in necrotic tumors after melanoma neoadjuvant anti-PD1 therapy correlate with pathological response and recurrence-free survival.
Kevin L MaTara C MitchellMeaghan DougherCimarron E SharonGabriella N TortorelloDavid E ElderEric E MorganPhyllis A GimottyAlexander C HuangRavi K AmaravadiLynn M SchuchterAhron FlowersJohn T MiuraGiorgos C KarakousisGeorge X XuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
CD3+ and CD8+ nTILs are associated with pathological response and 5-year RFS in melanoma patients after neoadjuvant anti-PD1 therapy.